Thursday, Par Pharmaceutical Companies Inc. (PRX) received final approval from the U.S. Food and Drug Administration or FDA for its Abbreviated New Drug Application for nateglinide tablets. Nateglinide is a generic version of Novartis' Starlix. Par will begin shipping the 60mg and 120mg strengths of nateglinide to the trade immediately. Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes mellitus.
Par Pharmaceutical Companies Inc., through its subsidiary, Par Pharmaceutical Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.